Ruchatz, A., Chester, J., Gough, M., Chong, H., Cosset, F-L., Diaz, R, M., Harrington, K., Álvarez-Vallina, L., & Vile, R. Tumour Antigen Specific Induction of Transcriptionally Targeted Retroviral Vectors from Chimeric Immune Receptor- Modified T Cells. Nature Biotech. (2002). 20:256-263.

Sanz, L., Pascual, M., Muñoz, A., González, M. A., Hernández Salvador, & Álvarez-Vallina, L. Development of a computer-assisted high-throughput screening platform for anti-angiogenic testing Microvascular Res. (2002). 63:335-339.

Sanz, L., Kristensen, P., Blanco, B., Facteau, S., Russell, S. J., Winter, G. & Álvarez-Vallina, L. Single-chain antibody-based gene therapy: Inhibition of tumor growth by in situ production of phage-derived antibodies blocking functionally active sites of cell-associated matrices. Gene Therapy. (2002). 9:1049-1053.

Sanz, L., García-Bermejo, L., Blanco, F. J., Kristensen, P., Feijoo, M., Suárez, E., Blanco, B.& Álvarez-Vallina, L. A novel cell binding site in the coiled-coil domain of laminin involved in capillary morphogenesis. EMBO J. (2003) 22:1508-1517.

Sanz, L. & Álvarez-Vallina, L. The Extracellular Matriz: a new turn-of-the-screww for anti-angiogenic strategies. Trends Mol. Med. (2003) 9:256-262.

Blanco, B., Holliger, P., Vile, R. & Álvarez-Vallina, L. Induction of human T-lymphocyte cytotoxicity and inhibition of tumor growth by tumor-specific diabody-based molecules secreted by gene-modified bystander cells. J. Immunol. (2003). 171:1070-1077.

Sanz, L., Blanco, B. & Álvarez-Vallina L. Antibodies and gene therapy: teaching old “magic bullets” new tricks. Trends Immunol. (2004). 25:85-91.

Urban JH, Schneider RM, Compte M, Finger C, Cichutek K, Álvarez-Vallina L, Buchholz CJ. Selection of functional human antibodies from retroviral display libraries. Nucleic Acids Res. (2005) 24:33-35..

Sanz L. & Álvarez-Vallina L. Antibody-based anti-angiogenic cancer therapy. Expert Opin Ther. Targets. (2005). 9:1235-45

Sánchez-Arévalo Lobo VJ, Cuesta AM, Sanz L, Compte M, Prieto J, Blanco FJ, Álvarez-Vallina, L. Enhanced antiangiogenic therapy with single-chain antibody-collagen XVIII NC1/endostatin domain fusion proteins engineered to exploit matrix remodelling events. Int. J. Cancer (2006) 119:455-62.

Compte, M., Blanco, B., Serrano, F., Cuesta, AM, Sanz, L., Bernad, A., Holliger, P. & Álvarez-Vallina, L. Inhibition of tumor growth in vivo by in situ secretion of bispecific anti-CEA x anti-CD3 diabodies from lentivirally transduced human lymphocytes. Cancer Gene Ther (2007) 14:380-388.